- Investment of more than €80 million to modernise Latin American
production sites.
- In Santiago de Chile, a 3,500-square-metre solids plant has
been completely refurbished, creating a world-class manufacturing
facility with a production capacity of 1.8 billion tablets
annually.
- In Quito, Ecuador, a new
1,800-square-metre plant will enable the production of 300 million
high-quality tablets annually for pain patients in 17 European
countries.
AACHEN, Germany ,
July 17,
2024 /PRNewswire/ -- Grünenthal, a leading
pharmaceutical company specializing in pain research and
management, has announced significant investments in its Latin
American production sites. These investments will enhance
Grünenthal's production network, ensuring a reliable supply of
medicines for patients across Latin
America, Europe, and
beyond.
Grünenthal operates a robust production network with five
manufacturing sites in Germany,
Switzerland, Italy, Chile,
and Ecuador. These sites produce
medicine from Grünenthal's portfolio and offer contract
manufacturing services to third parties. Grünenthal recently
invested over €80 million to enhance its production capabilities in
Latin America. To ensure
production excellence and expand the geographical reach of its
Latin American facilities, Grünenthal is implementing a
standardized approach to product robustness, quality, and
regulatory compliance across all its global manufacturing
sites.
"Our investment in Latin
America is a strong demonstration of our commitment to
long-term competitiveness in the region," says Victor Barbosa, Head of Global Operations and
member of the Executive Board Team. "Future-proofing our
manufacturing capabilities underscores our commitment to ensuring a
safe, reliable, and efficient supply of medicine to patients
globally. Grünenthal delivers high-quality medicine from
Latin America to the world—a
unique capability in the region."
Grünenthal has been operating in Santiago de Chile for 45 years. The company's largest
manufacturing investment in the past three decades, a new
3,500-square-meter facility in Chile, will enable a production capacity of up
to 1.8 billion tablets annually. This facility's state-of-the-art
technology reinforces Grünenthal's position as Chile's leading pharmaceutical manufacturer.
Additionally, the advanced technology will positively impact
employees by providing training and specialization, positioning
them at the forefront of the industry. Grünenthal aims to complete
the certification process with the European Medicines Agency (EMA)
by November 2025, enabling the supply
of medicines from Chile to
Europe.
Grünenthal's manufacturing site in Quito, Ecuador, is one of the few in
Latin America licensed to export
to Europe and the only one in
Ecuador with an EU Good
Manufacturing Practice certificate, setting a high industry
standard. The 50,000-square-metre campus is Ecuador's largest and most modern
manufacturing plant for solid, semi-solid, and liquid
pharmaceuticals. Starting in 2025, the new facility will produce up
to 300 million high-quality tablets annually for pain patients in
17 European countries.
About Grünenthal
Grünenthal is a global leader in pain management and related
diseases. As a science-based, fully integrated pharmaceutical
company, we have a long track record of bringing innovative
treatments and state-of-the-art technologies to patients worldwide.
Our purpose is to change lives for the better – and innovation is
our passion. We are focusing all our activities and efforts on
working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries
across Europe, Latin America, and the U.S. Our products are
available in approx. 100 countries. In 2023, Grünenthal employed
around 4,400 people and achieved revenues of €1.8 billion.
More information: https://www.grunenthal.com and Grünenthal
Report 2023/24
- Pictures are available at AP –
Follow us on:
LinkedIn: Grünenthal Group
Instagram: Grünenthal
Media Contact:
Jessica
Liu, Global Corporate Affairs & Communication
Email: jessica.liu@grunenthal.com
View original
content:https://www.prnewswire.com/news-releases/grunenthal-announces-significant-investments-in-its-latin-america-production-sites-further-securing-reliable-medicine-supply-for-patients-302199218.html
SOURCE Grünenthal Group